Publication

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies

Ruiz-Irastorza, G., Cuadrado, M. J., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V., Pierangeli, S., Tektonidou, M. & Khamashta, M., Feb-2011, In : Lupus. 20, 2, p. 206-218 13 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • G. Ruiz-Irastorza
  • M. J. Cuadrado
  • I. Ruiz-Arruza
  • R. Brey
  • M. Crowther
  • R. Derksen
  • D. Erkan
  • S. Krilis
  • S. Machin
  • V. Pengo
  • S. Pierangeli
  • M. Tektonidou
  • M. Khamashta

The antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or pregnancy morbidity in combination with the persistent presence of circulating antiphospholipid antibodies: lupus anticoagulant, anticardiolipin antibodies and/or anti-beta 2-glycoprotein I antibodies in medium to high titers. The management of thrombosis in patients with APS is a subject of controversy. This set of recommendations is the result of an effort to produce guidelines for therapy within a group of specialist physicians in Cardiology, Neurology, Hematology, Rheumatology and Internal Medicine, with a clinical and research focus on APS. Lupus (2011) 20, 206-218.

Original languageEnglish
Pages (from-to)206-218
Number of pages13
JournalLupus
Volume20
Issue number2
Publication statusPublished - Feb-2011

    Keywords

  • anticardiolipin, antiphospholipid, aspirin, hydroxychloroquine, lupus anticoagulant, prevention, stroke, thrombosis, warfarin, SYSTEMIC-LUPUS-ERYTHEMATOSUS, RISK-FACTORS, ANTICARDIOLIPIN ANTIBODIES, ISCHEMIC-STROKE, VENOUS THROMBOEMBOLISM, ANTITHROMBOTIC THERAPY, ANTICOAGULANT-THERAPY, PHOSPHOLIPID SYNDROME, RECURRENT THROMBOSIS, CLINICAL-OUTCOMES

ID: 5265102